ClinicalTrials.gg

Program

COVID-19 Vaccine

Also written as “Investigational COVID-19 Vaccine”.

Its studies are mostly in Influenza, Human, led by BioNTech.

Furthest: phase 2, since Nov 8, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech20 open or runningphase 2since Nov 8, 2024Nov 8, 2024none ahead

Also a collaborator on its studies: Pfizer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 8, 2024First study: phase 2 study in Influenza, HumanFirst studyNCT06683352 · 1,353 enrolled · United States
  2. Feb 7, 2025Phase 2 study in Influenza, HumanNCT06821061 · 2,650 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“COVID-19 Vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06821061Influenza, Human · United States2CompletedDec 17, 20252,650
NCT06683352Influenza, Human · United States2CompletedJul 15, 20251,353

How it is read

Names in the registry

  • “COVID-19 Vaccine”, 1 entry
  • “Investigational COVID-19 Vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.